Cutaneous adverse reactions to the new oral antiviral drugs against SARS‐CoV‐2.

In addition, all studies demonstrating clinical benefit of these drugs in patients with COVID-19 patients were conducted in unvaccinated individuals and most in unimmunized individuals with no previous infection. Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2 Currently, there are two oral antivirals directed to SARS-CoV-2: molnupiravir (Lagevrio SP ® sp ), which induces an antiviral effect via viral error catastrophe, and nirmatrelvir-ritonavir (Paxlovid™) (nirmatrelvir inhibits an enzyme needed for coronavirus replication and ritonavir decreases metabolism of nirmatrelvir, maintaining its antiviral activity at higher levels). [Extracted from the article]